HER2-targeted therapy

Abstract

Up to 25% of women with breast cancer have tumors, which are human epidermal growth factor receptor-2 (HER2) positive, associated with an aggressive phenotype, higher recurrence rate and reduced survival [1, 2]. In these patients with poorer prognosis, combination chemotherapy (±endocrine therapy), up until recently, was the only treatment modality available. © 2010 Springer Berlin Heidelberg.